SURMOUNT-OSA Trial: Tirzepatide Reduces Sleep Apnea Severity by Up to 63%

Medically reviewed by Dr. James Whitfield, DO, FACOI

The SURMOUNT-OSA trial, presented at the American Diabetes Association 2024 meeting, showed that tirzepatide reduced obstructive sleep apnea severity by up to 63% — approximately 30 fewer breathing interruptions per hour. These results raise the possibility that tirzepatide could become a pharmacological alternative to CPAP for obesity-related sleep apnea.

SURMOUNT-OSA: A New Approach to Sleep Apnea

Obstructive sleep apnea (OSA) affects an estimated 936 million adults worldwide, with obesity being the strongest modifiable risk factor. The current standard of care — continuous positive airway pressure (CPAP) — is effective but plagued by poor adherence, with up to 50% of patients unable to tolerate it long-term. The SURMOUNT-OSA trial demonstrated that tirzepatide could dramatically reduce sleep apnea severity through weight loss, potentially offering a pharmacological alternative [1]. For a deeper dive into this area, see testosterone's impact on sleep quality.

Understanding Obesity-Related Sleep Apnea

OSA occurs when excess tissue in the upper airway collapses during sleep, causing repeated breathing interruptions (apneas and hypopneas). The connection to obesity is direct:

Fat deposition: Excess fat around the neck, tongue, and pharynx narrows the airway

Abdominal obesity: Reduces lung volume and increases airway collapsibility

Inflammation: Obesity-related inflammation contributes to upper airway edema

Dose-response: Each 10% weight gain increases OSA risk by 6-fold

Weight loss of 10-15% has been shown to significantly improve OSA, making potent weight loss medications a logical treatment approach [2].

---

> Considering adding this to your protocol? Telegenix provides physician-supervised peptide and hormone optimization programs tailored to your bloodwork and goals. Schedule your consultation.

---

Study Design

SURMOUNT-OSA consisted of two parallel studies:

Study 1: Adults with moderate-to-severe OSA and obesity who were not using CPAP

Study 2: Adults with moderate-to-severe OSA and obesity who were using CPAP

Both studies shared key design features:

Randomized, double-blind, placebo-controlled

52-week treatment duration

Tirzepatide escalated to maximum tolerated dose (10 or 15 mg)

Primary endpoint: Change in apnea-hypopnea index (AHI) from baseline

Key Inclusion Criteria:

Age 18-65 years

BMI ≥30 kg/m²

Moderate-to-severe OSA (AHI ≥15 events/hour)

Baseline AHI: approximately 50-55 events/hour (severe range) [1]

Primary Results: AHI Reduction

The results were dramatic across both studies:

Study 1 (No CPAP):

Tirzepatide: AHI reduced by approximately 55-63% (~30 fewer events/hour)

Placebo: AHI reduced by approximately 6%

Treatment difference: Highly significant (P<0.001)

Study 2 (With CPAP):

Tirzepatide: AHI reduced by approximately 43-53%

Placebo: AHI reduced by approximately 8%

Treatment difference: Highly significant (P<0.001)

Clinical Severity Reclassification:

Many patients moved from severe to mild or even normal AHI categories

A substantial proportion achieved AHI <5 events/hour (considered resolved OSA)

Some patients in Study 2 were able to reduce or discontinue CPAP use [1]

Weight Loss Results

Weight loss was consistent with other SURMOUNT trials:

Mean weight loss: Approximately 18-20% in Study 1, 16-18% in Study 2

Waist circumference: Significant reduction

Neck circumference: Reduced, directly relevant to airway patency

BMI reduction: Many patients moved from obese to overweight categories

Beyond AHI: Comprehensive Sleep Improvements

Tirzepatide improved multiple sleep parameters:

Oxygen desaturation index: Significantly reduced

Time spent below 90% oxygen saturation: Decreased

Sleep quality scores: Improved on validated questionnaires

Daytime sleepiness (Epworth Sleepiness Scale): Significantly reduced

Patient-reported outcomes: Better sleep quality, less fatigue, improved daytime functioning

Cardiometabolic Benefits

The secondary cardiometabolic outcomes (published by Malhotra et al. in Nature Medicine, 2026) showed:

Blood pressure: Significant reductions in both systolic and diastolic BP

CRP: Reduced, indicating decreased systemic inflammation

HbA1c: Improved in patients with pre-diabetes

Lipid profile: Improved triglycerides and HDL cholesterol

Cardiac biomarkers: Reduced NT-proBNP, suggesting decreased cardiac stress [3]

These findings suggest that treating OSA with tirzepatide provides benefits beyond sleep improvement, addressing the cardiovascular risk that makes OSA so dangerous.

CPAP vs. Tirzepatide: A New Paradigm?

The results raise important questions about OSA treatment:

| Factor | CPAP | Tirzepatide |

|---|---|---|

| AHI reduction | 70-90% | 55-63% |

| Adherence | 50-60% long-term | Expected higher (weekly injection) |

| Weight effect | None | 18-20% loss |

| CV risk reduction | Modest | Significant |

| Quality of life | Improves if used | Improves broadly |

| Cost | Device + supplies | Medication cost |

While CPAP produces greater AHI reduction when used consistently, tirzepatide offers a more comprehensive approach by addressing the root cause (obesity) while also improving cardiometabolic health [1].

Clinical Implications

New treatment option: Tirzepatide offers a pharmacological approach for patients who cannot tolerate CPAP

Combination therapy: Using tirzepatide alongside CPAP may provide additive benefits

Root cause treatment: Unlike CPAP, tirzepatide addresses the underlying obesity driving OSA

Screening opportunity: OSA screening should be routine in patients starting tirzepatide for obesity

Potential FDA indication: These data support a potential FDA approval for tirzepatide in OSA

> Related Comparison: Ozempic vs Mounjaro: Complete Comparison

References

Malhotra A, Grunstein R, Engström J, et al. "Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity." New England Journal of Medicine. 2024. Presented at ADA 2024.

Peppard PE, Young T, Barnet JH, et al. "Increased prevalence of sleep-disordered breathing in adults." American Journal of Epidemiology. 2013;177(9):1006-1014. PubMed: 23589584

Malhotra A, Grunstein R, Azarbarzin A, et al. "Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial." Nature Medicine. 2026. PubMed: Available

---

> Ready to put this research into practice? Telegenix provides evidence-based peptide and TRT protocols supervised by licensed providers. Get a personalized plan built around your bloodwork. Start with a free consultation.

---